Aptadel Therapeutics

Aptadel Therapeutics is a preclinical-stage biotech company located in Barcelona, Spain. We are developing an RNA-based delivery platform for cancer treatment. The platform is based on Aptamer technologies. Our lead indication is Ewing Sarcoma, a rare variety of bone cancer, affecting children.